Payment overview · 2025
General Payments
$1,591.68
18 reported records · 11 companies
Healthcare provider profile · identity verified
Meyer Halberstam, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · BRONX, NY · NPI 1225026511
Verified facts
What the public records show
CMS Open Payments records show Meyer Halberstam, MD received $1,591.68 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 61.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 440 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 440 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $975.00 | 61.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $160.00 | 10.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.47 | 7.0% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $105.30 | 6.6% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $48.54 | 3.0% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $43.72 | 2.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.95 | 2.7% | 2 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.66 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $29.94 | 1.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.00 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.10 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $975.00 | 1 |
| Food and Beverage | $616.68 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $993.10 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $160.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $160.00 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $105.30 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $87.73 | 4 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $48.54 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $43.72 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $32.66 | 1 | 2025 |
Source payment records
|
|||||
| VPRIV Normalized: vpriv |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $29.94 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 440 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
440 | 75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
440 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
310 | 66 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
294 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 558 | 94 |
| Jardiance | Empagliflozin | 440 | 75 |
| Metformin Hcl | Metformin Hcl | 400 | 85 |
| Mounjaro | Tirzepatide | 310 | 66 |
| Trulicity | Dulaglutide | 294 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 36 |
| Repaglinide | Repaglinide | 191 | 35 |
| Ozempic | Semaglutide | 178 | 31 |
| Farxiga | Dapagliflozin Propanediol | 153 | 30 |
| Januvia | Sitagliptin Phosphate | 127 | 24 |
| Tradjenta | Linagliptin | 125 | 26 |
| Lisinopril | Lisinopril | 110 | 25 |
| Metformin Hcl Er | Metformin Hcl | 103 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 18 |
| Losartan Potassium | Losartan Potassium | 96 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 92 | 16 |
| Glimepiride | Glimepiride | 86 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 84 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 65 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 13 |
| Ezetimibe | Ezetimibe | 57 | 12 |
| Simvastatin | Simvastatin | 49 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | 16 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 40 | 13 |
| Methimazole | Methimazole | 38 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 38 | suppressed |
| Gabapentin | Gabapentin | 36 | suppressed |
| Prolia | Denosumab | 36 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | 11 |
| Alogliptin | Alogliptin Benzoate | 33 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Omeprazole | Omeprazole | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,591.68 · 18 records | Lilly USA, LLC | DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, GVOKE HYPOPEN, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Korlym, OTEZLA, Omnipod, RECORLEV, REPATHA, TEPEZZA, TRYNGOLZA, VPRIV, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error